Table 3. Univariate Analysis for Outcome... | American Society of Hematology

Table 3.

Univariate Analysis for Outcome at 7 Years

Characteristics	No. of Patients	EFS		Relapse		NRM
Characteristics	No. of Patients	%	P Value	%	P Value	%	P Value
Cytogenetic subgroup
Good	25	51		19		37
Intermediate	15	40	.004	12	.002	54	.23
Poor	17	6		82		68
GVHD prophylaxis
CSP/MTX ± other	42	37		32		45
Other	18	8	.04	74	.009	68	.48
Marrow blast count^*
≥5%	46	18		59		55
<5%	14	64	.03	0	.01	36	.35
Chronic GVHD
None	21	19		78		15
Present	23	54	.08	9	.006	40	.16
Prior chemotherapy
Yes	18	18		65		50
No	42	37	.15	27	.03	49	.86
BMT type
H/C sibling	37	30		47		42
Other	23	30	.32	23	.60	61	.13
Acute GVHD grade
Grade 0-I	26	31		53		35
Grade II-IV	34	30	.43	20	.23	62	.08
Sex
Male	26	18		59		57
Female	34	40	.47	28	.52	45	.66
Disease duration
<3 mo	31	26		51		47
≥3 mo	29	33	.75	31	.70	52	.52
Age
≤40 yr	31	33		37		47
>40 yr	29	28	.99	42	.70	53	.79

Characteristics	No. of Patients	EFS		Relapse		NRM
Characteristics	No. of Patients	%	P Value	%	P Value	%	P Value
Cytogenetic subgroup
Good	25	51		19		37
Intermediate	15	40	.004	12	.002	54	.23
Poor	17	6		82		68
GVHD prophylaxis
CSP/MTX ± other	42	37		32		45
Other	18	8	.04	74	.009	68	.48
Marrow blast count^*
≥5%	46	18		59		55
<5%	14	64	.03	0	.01	36	.35
Chronic GVHD
None	21	19		78		15
Present	23	54	.08	9	.006	40	.16
Prior chemotherapy
Yes	18	18		65		50
No	42	37	.15	27	.03	49	.86
BMT type
H/C sibling	37	30		47		42
Other	23	30	.32	23	.60	61	.13
Acute GVHD grade
Grade 0-I	26	31		53		35
Grade II-IV	34	30	.43	20	.23	62	.08
Sex
Male	26	18		59		57
Female	34	40	.47	28	.52	45	.66
Disease duration
<3 mo	31	26		51		47
≥3 mo	29	33	.75	31	.70	52	.52
Age
≤40 yr	31	33		37		47
>40 yr	29	28	.99	42	.70	53	.79

Abbreviations: EFS, event-free survival; NRM, nonrelapse mortality; GVHD, graft-versus-host disease; CSP, cyclosporine; MTX, methotrexate; BMT, bone marrow transplantation; H/C, histocompatible.

Highest bone marrow blast percentage before BMT.

[ViewLarge]

This Feature Is Available To Subscribers Only